Efficacy of Direct Injection of Etanercept into Knee Joints for Pain in Moderate and Severe Knee Osteoarthritis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Osteoarthritic (OA) pain is largely considered to be inflammatory pain. However, during the last stage of knee OA, sensorynerve fibers in the knee are shown to be significantly damaged when the subchondral bone junction is destroyed, and this can induce neuropathic pain. Several authors have reported that tumor necrosis factor-α (TNFα) in a knee joint plays a crucial role in pain modulation. The purpose of the current study was to evaluate the efficacy of etanercept, a TNFα inhibitor, for pain in knee OA. Materials and Methods: Thirty-nine patients with knee OA and a 2–4 Kellgren-Lawrence grading were evaluated in this prospectivestudy. Patients were divided into two groups; hyaluronic acid (HA) and etanercept injection. All patients received a single injectioninto the knee. Pain scores were evaluated before and 4 weeks after injection using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and they were compared between the groups. Results: Before injection, VAS and WOMAC scores were not significantly different between the groups (p>0.05). Significant pain relief was found in the etanercept group at 1 and 2 weeks by VAS, and at 4 weeks by WOMAC score, compared with the HA group (p<0.05). No adverse events were observed in either group. Conclusion: Direct injection of etanercept into OA knee joints was an effective treatment for pain in moderate and severe OA patients. Furthermore, this finding suggests that TNFα is one factor that induces OA pain.
Abstract
Purpose: Osteoarthritic (OA) pain is largely considered to be inflammatory pain. However, during the last stage of knee OA, sensorynerve fibers in the knee are shown to be significantly damaged when the subchondral bone junction is destroyed, and this can induce neuropathic pain. Several authors have reported that tumor necrosis factor-α (TNFα) in a knee joint plays a crucial role in pain modulation. The purpose of the current study was to evaluate the efficacy of etanercept, a TNFα inhibitor, for pain in knee OA. Materials and Methods: Thirty-nine patients with knee OA and a 2–4 Kellgren-Lawrence grading were evaluated in this prospectivestudy. Patients were divided into two groups; hyaluronic acid (HA) and etanercept injection. All patients received a single injectioninto the knee. Pain scores were evaluated before and 4 weeks after injection using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and they were compared between the groups. Results: Before injection, VAS and WOMAC scores were not significantly different between the groups (p>0.05). Significant pain relief was found in the etanercept group at 1 and 2 weeks by VAS, and at 4 weeks by WOMAC score, compared with the HA group (p<0.05). No adverse events were observed in either group. Conclusion: Direct injection of etanercept into OA knee joints was an effective treatment for pain in moderate and severe OA patients. Furthermore, this finding suggests that TNFα is one factor that induces OA pain.
참고문헌 (20)
- "National Center for Chronic Disease Prevention and Health Promotion" (2008)[URL]
- van der Kraan PM, "Development of osteoarthritic lesions in mice by “metabolic” and “mechanical” alterations in the knee joints", Am J Pathol, 135, pp.1001~1014 (1989)
- Ochiai N, "Extracorporeal shock wave therapy improves motor dysfunction and pain originating from knee osteoarthritis in rats", Osteoarthritis Cartilage, 15, pp.1093~1096 (2007)
- Ivanavicius SP, "Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation", Pain, 128, pp.272~282 (2007)
- Hochman JR, "The nerve of osteoarthritis pain", Arthritis Care Res (Hoboken), 62, pp.1019~1023 (2010)
- Seiji Ohtori, "Existence of a Neuropathic Pain Component in Patients with Osteoarthritis of the Knee", Yonsei Medical Journal, 53(4), pp.801~805 (2012), 연세대학교의과대학[DOI]
- Orita S, "Associations between proinflammatory cytokines in the synovial fluid and radiographic grading and pain-related scores in 47 consecutive patients with osteoarthritis of the knee", BMC Musculoskelet Disord, 12, pp.144~ (2011)
- Ogino S, "Detection of pain-related molecules in the subchondral bone of osteoarthritic knees", Clin Rheumatol, 28, pp.1395~1402 (2009)
- Walsh DA, "Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis", Rheumatology (Oxford), 49, pp.1852~1861 (2010)
- Nelson AE, "A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative", Semin Arthritis Rheum, 43, pp.701~712 (2014)
- Bellamy N, "Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee", J Rheumatol, 15, pp.1833~1840 (1988)
- Kellgren JH, "Radiological assessment of osteoarthritis", Ann Rheum Dis, 16, pp.494~501 (1957)
- Lane NE, "Tanezumab for the treatment of pain from osteoarthritis of the knee", N Engl J Med, 363, pp.1521~1531 (2010)
- Balanescu AR, "Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial", Ann Rheum Dis, 73, pp.1665~1672 (2014)
- Nagashima H, "Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study", Osteoarthritis Cartilage, 19, pp.1405~1412 (2011)
- Ohtori S, "Spinal neural cyclooxygenase-2 mediates pain caused in a rat model of lumbar disk herniation", J Pain, 5, pp.385~391 (2004)
- Olmarker K, "Tumor necrosis factor alpha and nucleuspulposus-induced nerve root injury", Spine (Phila Pa 1976), 23, pp.2538~2544 (1998)
- Korhonen T, "Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up", Spine (Phila Pa 1976), 29, pp.2115~2119 (2004)
- Ohtori S, "Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study", Spine (Phila Pa 1976), 37, pp.439~444 (2012)
- Maksymowych WP, "Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee", Arthritis Res Ther, 14, pp.R206~ (2012)